- Kraft to Formalize Hostile Cadbury Bid on Monday
- GE, Comcast Agree on NBC Universal Valuation
- US Health Care Reforms Face Tough Path in Senate
- Northrop to Sell $1.65 Billion Unit to Private Equity
- Obama Delays Start of Asia Trip to Attend Memorial
- China Urges US to Control Deficit to Stabilize Dollar
- BofA Board in Civil War Over Lewis' Succesor
- US Home Values Follow Sales Higher, For Some
- Hottest Zip Codes for Home Prices
- Tamminen: Why Does Oklahoma Want To Drown New York?
- Food Network, HGTV Drive Scripps Networks' Upside Surprise
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Anti-corruption activists gather in Doha
- Allianz makes Q3 net profit of euro1.32 billion
- Deadline looms for Kraft to make Cadbury bid
- Puma Q3 net income falls 24 percent to euro68 million
- AXA Asia Pacific Holdings spurns $10B takeover bid
- GM says China sales more than double in October
- Industry pushes chocolate milk in schools
- Study says APEC is as good as free trade area
- Precision Machine opening plant in Sturgis, SD
Text Size 
NEW YORK - GlaxoSmithKline PLC received FDA approval for its drug Arzerra as a treatment for chronic lymphocytic leukemia, a slowly progressing cancer of the blood and bone marrow.
The FDA said in a statement Monday that the approval applies to patients who have already received other forms of chemotherapy, which are no longer effective at controlling the condition.
Arzerra, a monoclonal antibody, binds to a specific protein found on the surface of both normal and malignant B cells, making the cells more susceptible to immune system attack.
Chronic lymphocytic leukemia primarily affects people older than 50 and arises from a group of white blood cells known as B-cells that are part of the body's immune system. Each year, about 16,000 people are diagnosed with the disease and about 4,400 people die from the disease.
The FDA approved Azerra under its accelerated approval process, which aims to speed drugs to market for patients with limited treatment options.
As part of that process, GlaxoSmithKline is conducting a clinical trial in chronic lymphocytic leukemia patients to confirm that the addition of Arzerra to standard chemotherapy delays the progression of the disease.
The most serious side effect of the drug is a potentially fatal brain infection called progressive multifocal leukoencephalopathy.
Print
Email
- Rumors abound that Oprah will leave her show to start a new network. What would this mean for daytime TV?
- A private equity specialist sponsored a stand-up comedy troupe in New York to prove that CEOs can, in fact, be funny.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- Did Hideki Matsui’s performance make it more likely that the Yankees will pay to have him back?
- Which wines should you bring—or serve—with holiday meals this year? Ask a connoisseur.
- Two competitors in this year’s World Series of Poker in Las Vegas have stories fit for Hollywood.
Data is a real-time snapshot *Data is delayed at least 15 minutes